Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|September 14, 2021
Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacyJames Harber, Tamihiro Kamata, Catrin Pritchard, et al.Expert Opinion on Emerging Drugs|June 26, 2009
Malignant pleural mesothelioma: current treatments and emerging drugsCarmen Belli, Dean Fennell, Monica Giovannini, et al.Expert Review of Respiratory Medicine|April 22, 2010
Translational therapies for malignant pleural mesotheliomaCarmen Belli, Santosh Anand, Gianfranco Tassi, et al.Plos One|March 10, 2011
Robust automated tumour segmentation on histological and immunohistochemical tissue imagesChing-Wei Wang, Dean Fennell, Ian Paul, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapyJohn D O'Flaherty, Martin Barr, Dean Fennell, et al.Lung Cancer (Amsterdam, Netherlands)|January 3, 2012
Circulating tumour cells, their role in metastasis and their clinical utility in lung cancerJohn D O'Flaherty, Steven Gray, Derek Richard, et al.Epigenomics|August 17, 2016
KDM6B histone demethylase is an epigenetic regulator of estrogen receptor β expression in human pleural mesotheliomaArcangela G Manente, Giulia Pinton, Sara Zonca, et al.Oncotarget|February 18, 2016
SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cellsGiulia Pinton, Sara Zonca, Arcangela G Manente, et al.Lung Cancer (Amsterdam, Netherlands)|May 20, 2008
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesotheliomaJustin Stebbing, Thomas Powles, Kirsty McPherson, et al.The Lancet. Oncology|June 7, 2024
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 studyJoachim G Aerts, Robert Belderbos, Paul Baas, et al.Pageof 3